Biotech News

Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair

Humacyte (HUMA)Humacyte2026-03-17 12:00 ESTFDA / regulatory

- Humacyte is also pursuing a mechanism for making Symvess available in Israel on a hospital-by-hospital basis in advance of MAA approval - - Preparation is underway for expansion of Symvess into other countries, including in the Middle East - DURHAM, N.C., March 17, 2026 (GLOBE NEWSWIRE) --

Humacyte

Bioengineered Human Tissue Platform Humacyte develops implantable vascular conduits manufactured from human vascular cells and designed to become repopulated by the patient's own cells. The platform is intended to produce universally implantable tissues at commercial scale. SYMVESS SYMVESS is an FDA-approved acellular tissue-engineered...

Recent company news

HUMAHumacyte2026-08-24 12:00 EST

Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions

HUMAHumacyte2026-08-19 12:00 EST

Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results

HUMAHumacyte2026-08-18 12:00 EST

Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”

HUMAHumacyte2026-08-12 11:00 EST

Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update

HUMAHumacyte2026-08-07 12:00 EST

Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026

Stock data

Close: 0.64 USD
Market cap: 308.61M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States